Finch Therapeutics Group, Inc.
FNCH
$13.45
-$0.55-3.93%
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -100.00% | -100.00% | -87.57% | -93.07% | -98.03% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.00% | -100.00% | -87.57% | -93.07% | -98.03% |
| Cost of Revenue | -100.00% | -99.54% | -86.38% | -66.59% | -48.81% |
| Gross Profit | 100.00% | 99.54% | 86.36% | 65.78% | 35.32% |
| SG&A Expenses | -46.96% | -38.31% | -25.65% | -2.94% | 30.83% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -70.93% | -71.93% | -61.70% | -43.37% | -23.18% |
| Operating Income | 70.82% | 71.72% | 61.45% | 42.42% | 10.39% |
| Income Before Tax | 89.89% | 89.55% | 31.78% | 4.23% | -83.72% |
| Income Tax Expenses | 100.00% | 100.00% | -- | -- | -- |
| Earnings from Continuing Operations | 89.63% | 89.32% | 34.80% | 7.47% | -79.18% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 89.63% | 89.32% | 34.80% | 7.47% | -79.18% |
| EBIT | 70.82% | 71.72% | 61.45% | 42.42% | 10.39% |
| EBITDA | 69.15% | 69.88% | 60.72% | 42.59% | 11.30% |
| EPS Basic | 89.68% | 89.38% | 35.33% | 8.32% | -77.59% |
| Normalized Basic EPS | 77.24% | 78.99% | 68.62% | 49.45% | 17.35% |
| EPS Diluted | 89.68% | 89.38% | 35.33% | 8.32% | -77.59% |
| Normalized Diluted EPS | 77.24% | 78.99% | 68.62% | 49.45% | 17.35% |
| Average Basic Shares Outstanding | 0.41% | 0.69% | 0.94% | 1.04% | 0.97% |
| Average Diluted Shares Outstanding | 0.41% | 0.69% | 0.94% | 1.04% | 0.97% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
